Epidemiology of PCa: Malaysia

In Malaysia, prostate cancer is the third most common cancer among men.



Prescription-writing-Cover
 

The Malaysia National Cancer Registry reported that it is most common among Chinese, followed by Indian and Malay. The incidence is increasing in Malaysia.



Prescription-writing-Cover
 

WHO 2018: Age adjusted death rate for prostate cancer in Malaysia is 5.77 per 100,000 population.


These relatively low incidences could be a result of lower screening rates. The incidence of prostate cancer in Asia is also on the rise. Despite interregional variations, currently, Asia accounts for 33% of prostate cancer related deaths worldwide.


Relative survival at 5-year for prostate cancer is 73.0.


5-year relative survival of early stage PCa >98%, whereas metastatic prostate cancer (de novo) is associated with a median overall survival of 4-6 years depending on the burden of disease.


References:

  1. Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries [published correction appears in CA Cancer J Clin. 2020 Jul;70(4):313]. CA Cancer J Clin. 2018;68(6):394-424. doi:10.3322/caac.21492
  2. Aziah AM, Hashimah B, Nirmal K, Siti Zubaidah AR, Puteri NA, Nabihah A, Sukumaran R, Balqis B, Nadia SM, Sharifah SS. Malaysia National Cancer Registry Report (MNCR) 2012–2016. Putrajaya, Ministry of Health Malaysia, 2019.
  3. National Cancer Institute. Malaysian Study On Cancer Survival (MySCan). Putrajaya, Ministry of Health Malaysia, 2018.
  4. Ng K, Smith S, Shamash J. Metastatic Hormone-Sensitive Prostate Cancer (mHSPC): Advances and Treatment Strategies in the First-Line Setting. Oncol Ther. 2020;8(2):209-230. doi:10.1007/s40487-020-00119-z
  5. Sung H, Ferlay J, Siegel RL, et al. Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. CA Cancer J Clin. 2021;71(3):209-249. doi:10.3322/caac.21660